Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.

Understand RA from early to advanced stages. Explore symptoms, treatments, and lifestyle tips to manage rheumatoid arthritis ...

Indian scientists have created an innovative self-actuating drug delivery system for Rheumatoid Arthritis, providing precise ...

The positive trial results have not only demonstrated rosnilimab's potential in treating RA but have also validated AnaptysBio's scientific approach in targeting PD-1 co-inhibitory receptors on ...

Rheumatoid arthritis (RA) is an inflammatory arthritis characterized by chronic joint inflammation, cartilage degradation, and bone erosion.

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.

Shares of AnaptysBio (NASDAQ:ANAB) climbed ~12% in the premarket on Wednesday after the biotech said its lead asset, rosnilimab, reached the main goals in a mid-stage trial targeted at the autoimmune ...

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.